Jennifer L Johnston

Address:

9810 Chiselhurst Dr, Houston, TX 77065

VIN:

1J8FT28W58D547798

Make:

JEEP

Model:

PATRIOT

Year:

2008

US Patent:

7790365, Sep 7, 2010

Filed:

Jan 31, 2008

Appl. No.:

12/024032

Inventors:

Jennifer A. Johnston - Mill Valley CA, US
Alfred Goldberg - Chestnut Hill MA, US

Assignee:

Elan Pharma International Limited - Monksland, Athlone, County Westmeath

International Classification:

C12Q 1/00

US Classification:

435 4

Abstract:

The invention provides in vitro and cell-based assays for parkin activity, in which parkin-mediated ubiquitination of the S5a subunit of the 26S proteasome is measured, or ubiquitination of troponin 1. The assays may be used to screen for agents that modulate parkin protein ligase activity.

US Patent:

8017348, Sep 13, 2011

Filed:

Jul 21, 2008

Appl. No.:

12/177100

Inventors:

Jennifer A. Johnston - Mill Valley CA, US

Assignee:

Elan Pharma International Limited - Monksland, Athlone, County Westmeath

International Classification:

G01N 33/567
G01N 33/53
C12Q 1/68
C12N 1/21
C12N 15/85
C12N 15/00
C40B 30/00

US Classification:

435 721, 435 71, 435 6, 4352523, 435325, 4353201, 506 7

Abstract:

The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function.

US Patent:

8062839, Nov 22, 2011

Filed:

May 21, 2008

Appl. No.:

12/124984

Inventors:

Jennifer A. Johnston - Mill Valley CA, US
Colleen Tsui Cutcliffe - San Francisco CA, US

Assignee:

Elan Pharma International Limited - Athlone, County Westmeath

International Classification:

C12Q 1/00

US Classification:

435 4

Abstract:

The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity.

US Patent:

8502016, Aug 6, 2013

Filed:

Feb 10, 2006

Appl. No.:

11/352403

Inventors:

Jennifer A Johnston - Mill Valley CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

G01N 33/00
A01K 67/00

US Classification:

800 9, 800 3

Abstract:

The invention provides transgenic animals having a transgene comprising a genomic human alpha synuclein segment including six exons, five introns and at least one mutation associated with synucleinopathic disease operably linked to a human alpha synuclein promoter. The transgenic animals have characteristics of synucleinopathic disease including elevated levels of alpha synuclein in the brain, formation of intracellular deposits of alpha synuclein that have at least one, and preferably all features of Lewy bodies, formation of alpha-synuclein fragments, or phosphorylated forms of alpha synuclein, loss of neuronal cells, glial cells or oligodentricytes, impairment of motor function and/or impairment of cognitive function.

US Patent:

20070212679, Sep 13, 2007

Filed:

Dec 12, 2006

Appl. No.:

11/638242

Inventors:

Jennifer Johnston - Mill Valley CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12Q 1/00
G01N 33/567

US Classification:

435004000, 435007200

Abstract:

The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function. The invention also provides recombinant, enzymatically active, Parkin protein produced in prokaryotic expression systems, such as cells. Methods for purification of Parkin protein are also provided.

US Patent:

20090226946, Sep 10, 2009

Filed:

Jan 29, 2009

Appl. No.:

12/362448

Inventors:

Jennifer A. Johnston - Mill Valley CA, US
Balazs G. Szoke - San Carlos CA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12Q 1/48
C12Q 1/00

US Classification:

435 15, 435 4

Abstract:

The invention provides highthroughput screening assays to identify agents useful for treatment of Parkinson's Disease. In one embodiment the assay includes exposing a plurality of test samples, each containing a test compound and parkin protein, to thermal destabilization conditions and determining parkin ligase activity in the test samples relative to a control sample not containing a test agent. A test agent contained in a test sample in which parkin ligase activity exceeds the ligase activity in said control sample is identified as a candidate compound for treatment of Parkinson's Disease.

US Patent:

20090317825, Dec 24, 2009

Filed:

Dec 12, 2006

Appl. No.:

12/096890

Inventors:

Jennifer A. Johnston - Mill Valley CA, US

International Classification:

G01N 33/53
C12Q 1/02
C12N 9/00
C07K 1/00

US Classification:

435 71, 435 29, 435183, 435272

Abstract:

The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function. The invention also provides recombinant, enzymatically active, Parkin protein produced in prokaryotic expression systems, such as cells. Methods for purification of Parkin protein are also provided.

US Patent:

20120083003, Apr 5, 2012

Filed:

Oct 18, 2011

Appl. No.:

13/276175

Inventors:

Jennifer A. Johnston - Mill Valley CA, US
Colleen Tsui Cutcliffe - Menlo Park CA, US

Assignee:

Elan Pharma International Limited - Athlone

International Classification:

G01N 33/566

US Classification:

435 721

Abstract:

The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity.